Current status of 10B-neutron capture therapy: Enhancement of tumor dose via beam filtration and dose rate, and the effects of these parameters on minimum boron content: A theoretical evaluation

Fairchild, R.G.; Bond, V.P.

doi:10.1016/0360-3016(85)90318-9

Cited by 175 publications

(48 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…I . CARLSSON ET AL cells and effects of different spatial "B distributions (38)(39)(40)(41). From these calculations it can be deduced that the local concentration of '"B in the neigbourhood of the critical radiation target, DNA, must be more than 10 ppm (10 pg/ 9).…”

Section: Boron Concentrationsmentioning

confidence: 99%

“…Thermal and epithermal neutrons are easily obtained from nuclear reactors. The clinical tests with BSH-based BNCT against gliomas in Brookhaven, Massachusetts, and more recently in Japan (5-9, 39, 84), showed that thermal neutrons d o not have a good penetration across the skull and it is therefore thought that reactor-produced epithermal neutrons preferably should be used (39). The epithermal neutrons are thermalized within the brain and will then have the ideal energy for capturing by ' OB.…”

Section: Neutron Beamsmentioning

confidence: 99%

See 1 more Smart Citation

Present Status of Boron Neutron Capture Therapy

1992

View full text Add to dashboard Cite

Section: Boron Concentrationsmentioning

confidence: 99%

Section: Neutron Beamsmentioning

confidence: 99%

Present Status of Boron Neutron Capture Therapy

1992

View full text Add to dashboard Cite

“…1,2 For this therapy to be successful, boron-10 must be accumulated in concentrations of more than 10-20 ppm in the target tissue. 3,4 For the therapy to be successful, the chemical form of the boron compounds, and their possible binding to components of the blood and tissues, are of little importance as long as there is a sufficient amount of boron in the target tissue. As the amount of boron in the tumor should be as high as possible, compounds should contain boron units with as many boron atoms as possible.…”

Section: Introductionmentioning

confidence: 99%

Hemorrhage in mouse tumors induced by dodecaborate cluster lipids intended for boron neutron capture therapy

Schaffran¹,

Jiang²,

Bergmann³

et al. 2014

IJN

View full text Add to dashboard Cite

The potential of boron-containing lipids with three different structures, which were intended for use in boron neutron capture therapy, was investigated. All three types of boron lipids contained the anionic dodecaborate cluster as the headgroup. Their effects on two different tumor models in mice following intravenous injection were tested; for this, liposomes with boron lipid, distearoyl phosphatidylcholine, and cholesterol as helper lipids, and containing a polyethylene glycol lipid for steric protection, were administered intravenously into tumor-bearing mice (C3H mice for SCCVII squamous cell carcinoma and BALB/c mice for CT26/WT colon carcinoma). With the exception of one lipid (B-THF-14), the lipids were well tolerated, and no other animal was lost due to systemic toxicity. The lipid which led to death was not found to be much more toxic in cell culture than the other boron lipids. All of the lipids that were well tolerated showed hemorrhage in both tumor models within a few hours after administration. The hemorrhage could be seen by in vivo magnetic resonance and histology, and was found to occur within a few hours. The degree of hemorrhage depended on the amount of boron administered and on the tumor model. The observed unwanted effect of the lipids precludes their use in boron neutron capture therapy.

show abstract

“…The number of 10 B atoms incorporated into tumor cells is a critical factor that determines the specific, powerful killing effect of BNCT. It is reported that 15 to 30 Ag 10 B/g must be present in tumors and low levels in normal tissue, and that a sufficient number of thermal neutrons must reach a tumor for BNCT to be successful (4,5).…”

Section: Introductionmentioning

confidence: 99%

Improvement of the Tumor-Suppressive Effect of Boron Neutron Capture Therapy for Amelanotic Melanoma by Intratumoral Injection of the Tyrosinase Gene

et al. 2006

View full text Add to dashboard Cite

Boron neutron capture therapy (BNCT) is successful when there is a sufficient 10 B concentration in tumor cells. In melanoma, 10 B-para-boronophenylalanine (BPA) accumulation is proportional to melanin-producing activity. This study was done to confirm enhancement of the tumor-suppressive effect of BNCT on amelanotic melanoma by intratumoral injection of the tyrosinase gene. D178 or FF amelanotic melanomas were implanted s.c. in Syrian hamsters. One group of D178-or FF-bearing hamsters (TD178 or TFF group) received intratumoral injections of pcDNA-Tyrs constructed as a tyrosinase expression plasmid. The other hamsters (pD178 and pFF groups) were injected with pUC119, and control hamsters (D178 and FF groups) only with transfection reagents. All the groups underwent immunofluorescence analysis of tyrosinase expression and BPA biodistribution studies. BNCT experiments were done at the Kyoto University Research Reactor. Tyrosinase expression increased in the tumors of the TD178 and TFF groups but remained the same in the pD178 and pFF groups. Tumor boron concentrations in the TD178 and TFF groups increased significantly (TD178: 49.7 F 12.6 versus D178: 27.2 F 4.9 Mg/g, P < 0.0001; TFF: 30.7 F 6.6 versus FF: 13.0 F 4.7 Mg/g, P<0.0001). The BNCT tumor-suppressive effect was marked in the TD178 and TFF groups. In vivo transfection with the tyrosinase gene increased BPA accumulation in the tumors, the BNCT tumor-suppressive effect on amelanotic melanoma being significantly enhanced. These findings suggest a potential new clinical strategy for the treatment of amelanotic melanoma with BNCT. (Cancer Res 2006; 66(7): 3747-53)

show abstract

Current status of 10B-neutron capture therapy: Enhancement of tumor dose via beam filtration and dose rate, and the effects of these parameters on minimum boron content: A theoretical evaluation

Cited by 175 publications

References 6 publications

Present Status of Boron Neutron Capture Therapy

Present Status of Boron Neutron Capture Therapy

Hemorrhage in mouse tumors induced by dodecaborate cluster lipids intended for boron neutron capture therapy

Improvement of the Tumor-Suppressive Effect of Boron Neutron Capture Therapy for Amelanotic Melanoma by Intratumoral Injection of the Tyrosinase Gene

Contact Info

Product

Resources

About